Moderna and Recordati Partner on mRNA-3927
Analysis based on 14 articles · First reported Jan 29, 2026 · Last updated Jan 29, 2026
The collaboration between Moderna and Recordati for mRNA-3927 is expected to positively impact the pharmaceutical and biotechnology markets, particularly in the rare disease segment. It signals potential for a new disease-modifying treatment for Propionic Acidemia, which could create new revenue streams for both Moderna and Recordati.
Moderna and Recordati have announced a strategic collaboration and license agreement to develop and commercialize mRNA-3927, an investigational product for the treatment of Propionic Acidemia (PA). Under the terms, Moderna will lead the clinical development of mRNA-3927, while Recordati will be responsible for global commercialization upon approval. Recordati will make an upfront payment of $50 million to Moderna, with potential additional payments of up to $110 million in near-term development and regulatory milestones, as well as commercial milestones and tiered royalties on net sales. mRNA-3927 is an mRNA-based therapeutic designed to restore propionyl-CoA carboxylase enzyme activity in patients with PA, a rare inherited metabolic disorder. Interim clinical data has shown early signs of improvement, and a registrational study has reached target enrollment, with data readout expected by the end of 2026. This partnership aims to address a significant unmet medical need for Propionic Acidemia patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard